Protalex, Inc. Now Listed on OTC Bulletin Board; Announces Animal Testing Aimed at Novel Approach to Arthritis

    ALBUQUERQUE, N.M., March 22 /PRNewswire/ -- Protalex, Inc.
 (OTC Bulletin Board:   PRTX), a biopharmaceutical firm, announced today two
 significant milestones in its recent history.  First, the company, formerly
 known as Enerdyne Corporation, has returned to trading on the OTC Bulletin
 Board with a new symbol (PRTX) and a new mission:  developing a novel approach
 to treating Rheumatoid Arthritis.  Second, the company announced the
 successful completion of the cell culture phase of its research plan, and the
 beginning of animal studies of its unique BioRegulator product.  John Doherty,
 Protalex's President, announced, "The Protalex BioRegulator drug methodology
 operates on a completely different principle than existing treatment regimens.
 It works with the host's own natural defense system to arrest the disease
 process, rather than simply masking the symptoms."
     The unique Protalex technology is based upon discoveries made by Paul
 Mann, Ph.D., over decades of research into the immune system.  Dr. Mann, a
 Director of the Company and head of Research and Product Development, has
 explored the properties of several products that affect the "information
 management" mechanisms in the body.  Cells normally communicate with each
 other by chemical signals that pass back and forth to keep their functions in
 balance.  In many disease states, it is thought that erroneous signals cause
 garbled messages that lead to abnormal cell function and tissue damage.  Dr.
 Mann discovered that certain natural and synthetic compounds can restore
 aspects of the normal balance between tissues, halting the disease process
 itself.  This means that treatment can be discontinued once normal tissue
 functioning is re-established.  Furthermore, if the disease process is one
 that involves differentiation of cells, some degree of repair of damaged
 tissues should be expected.  These concepts are crucial for the treatment of
 Rheumatoid Arthritis.
     Rheumatoid arthritis affects more than 2 million people in the United
 States alone, most of whom are less than 65 years old.  Presently there is no
 effective cure for this chronic and disabling disorder, and available
 medications provide variable relief of symptoms but have only minimal effect
 upon the disease process.  The Protalex BioRegulator product promises to be
 the prototype for an entirely new class of drugs that can arrest or even
 reverse the course of the disease and thereby restore the quality of life for
 hundreds of thousands of people suffering from Rheumatoid Arthritis.
 
     Statements in this press release that are not strictly historical are
 "forward-looking" statements within the meaning of Section 27A of the
 Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
 These statements involve a high degree of risk and uncertainty, are
 predictions only and actual events or results may differ materially from those
 projected in such forward-looking statements.  Factors that could cause or
 contribute to differences include the Company's limited operating history,
 uncertainty regarding viability and market acceptance of the Company's
 products, and the Company's dependence on reimbursement by third parties.
 These factors and others are more fully described in the section entitled
 "Risks Related to the Company's Business" in the Company's Registration
 Statement on Form 10-SB (File No. 000-28385) as filed with the Securities and
 Exchange Commission.
 
 

SOURCE  Protalex, Inc.